📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-24 20:26
13 analysed today
13
Today
133,655
All-time analysed
40,136
Positive
6,284
Negative
79,413
Neutral
7,754
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
33 announcements match the current filters (relevance ≥ 5).
Rossari Biotech Q1 FY27: Record Quarterly Revenue of ~₹700 Cr, Up 28% YoY
Rossari Biotech achieved its highest-ever quarterly revenue of approximately ₹700 crore in Q1 FY27, representing a 28% YoY growth. The Home, Personal Care and Performance Chemicals (HPPC) segment was the primary driver, crossing the ₹550 crore milestone. While net debt reduced to ₹248 crore from ₹280 crore in March 2026, interest costs rose to ₹11 crore as previous CAPEX projects were capitalized. Management is focusing on B2B scaling and international expansion, including a new greenfield plant in Thailand and a planned entry into Saudi Arabia.
Confidence: HIGH
What changedThe company has transitioned from a heavy investment phase to an operational phase, with record revenues now being supported by recently commissioned capacities.
Why it mattersThe scale-up to a ₹700 Cr quarterly revenue base (approx. 29% of TTM revenue) demonstrates successful integration of acquisitions and capacity expansions, though margin improvement remains the next critical milestone.
Q1 Revenue: ₹700 CrHPPC Segment Revenue: ₹550 CrNet Debt: ₹248 CrInterest Cost (Q): ₹11 CrAndheri Office Sale: ₹10.5 Cr
📅 Short termThe market is likely to react positively to the record revenue and debt reduction, though the rise in interest costs may temper immediate bottom-line expectations.
📈 Long termStructural growth is supported by a 367,100 MTPA capacity and expansion into Southeast Asia and MENA regions, targeting a long-term revenue potential of ₹3,500 Cr.
⚠ Risk flags
- Margin pressure from raw material (Ethylene Oxide) pricing
- Intense competition in the specialty chemicals segment
- Rising interest costs impacting net profit
Key Highlights
Consolidated revenue grew 28% YoY to reach a record quarterly run-rate of ~₹700 Cr
HPPC segment revenue crossed the ₹550 Cr milestone, growing 28% YoY
Net debt reduced by ₹32 Cr during the quarter to ₹248 Cr
Interest expense increased to ₹11 Cr as term loans for completed CAPEX projects hit the P&L
Asset monetization continued with the sale of an Andheri office for ₹10.5 Cr
👀 What to Watch
Monitor the utilization levels of the ethoxylation and MDEA plants over the next 12 months, as management expects these to drive margin recovery toward normalized levels.
Rossari Biotech Shareholders Approve FY26 Dividend and Material RPT with Unitop Chemicals
Rossari Biotech concluded its 17th Annual General Meeting on July 20, 2026, where shareholders approved all eight proposed resolutions with over 99.99% majority. Key approvals include the adoption of FY26 financial statements, declaration of a dividend, and a material related party transaction (RPT) with Unitop Chemicals Private Limited. The company confirmed that dividends will be credited to eligible members within 10 working days. Additionally, the appointment and re-appointment of three directors, including two independent directors, were ratified.
Confidence: HIGH
What changedThe company has received formal shareholder mandate for its FY26 financial results, dividend payouts, and critical related-party business dealings with its subsidiary/associate Unitop Chemicals.
Why it mattersThe approval of the material RPT with Unitop Chemicals is significant as Rossari is investing INR 128 Cr in Unitop to expand ethoxylation capacity, which is a core part of its growth strategy to reach a revenue potential of INR 3,500 Cr.
Dividend Credit Timeline: 10 working daysRPT Approval (Votes in Favor): 99.9961%Total Shareholders on Record Date: 89,110Corporate Representative Shareholding: 14.87%
📅 Short termThe stock is likely to remain neutral as the AGM outcomes were in line with expectations and no major negative surprises were reported.
📈 Long termThe long-term focus remains on the company's ability to scale its recently commissioned 367,100 MTPA capacity and maintain its 15% core EBITDA margins in the B2B segment.
⚠ Risk flags
- Related-party transactions with Unitop Chemicals
- Intense competition in the specialty chemicals segment restricting pricing power
Key Highlights
All 8 resolutions passed with a requisite majority, with most receiving over 99.99% of valid votes in favor.
Material Related Party Transaction with Unitop Chemicals approved with 8,335,359 votes in favor (99.99% of non-promoter votes).
Dividend for the financial year ended March 31, 2026, approved for distribution within 10 working days.
A total of 48 shareholders attended the meeting via Video Conferencing, representing 14.87% of the total paid-up equity share capital.
Re-appointment of Executive Chairman Mr. Edward Menezes and appointment of two Independent Directors confirmed.
👀 What to Watch
Investors should verify the receipt of the FY26 dividend in their registered bank accounts within the next 10 working days and monitor the execution of the 367,100 MTPA capacity scale-up mentioned in the Chairman's address.
28% Revenue Growth in Q1 FY27; Rossari Biotech Reports Highest-Ever Quarterly Revenue
Rossari Biotech delivered a robust Q1 FY27 with consolidated revenue growing 28% YoY to Rs 697.2 crore, marking its highest-ever quarterly performance. EBITDA grew 19% to Rs 80.6 crore, although margins contracted slightly to 11.6% from 12.5% in the previous year. Net profit (PAT) saw a modest 4% increase to Rs 35.1 crore. The company also announced the establishment of a 5,000 MTPA greenfield blending facility in Thailand to strengthen its Southeast Asian presence.
Confidence: HIGH
What changedRossari has achieved record-high quarterly revenue and EBITDA while initiating localized manufacturing in Southeast Asia via a new Thailand facility.
Why it mattersThe strong top-line growth across all segments indicates successful market penetration and scaling of recently added capacities, though the lag in PAT growth suggests rising operational or financial costs.
Q1 FY27 Revenue: Rs 697.2 croreRevenue Growth (YoY): 28%EBITDA Margin: 11.6%Thailand Facility Capacity: 5,000 MTPAQ1 Revenue vs TTM Revenue: 29.1%
📅 Short termThe record revenue and EBITDA are likely to be viewed positively by the market, though the narrow 4% PAT growth may limit the upside in the immediate term.
📈 Long termThe expansion into Thailand and the monetization of non-core assets support a leaner, more globalized business model, aligning with the company's target of Rs 3,500 Cr revenue potential.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- EBITDA margin contraction of 90 bps YoY
- PAT growth (4%) significantly lagging revenue growth (28%)
- Intense competition limiting pricing power
Key Highlights
Consolidated revenue increased 28% YoY to Rs 697.2 crore, representing approximately 29% of TTM revenue.
EBITDA reached a record Rs 80.6 crore, up 19% YoY, despite a 90 bps margin compression to 11.6%.
All three business segments (HPPC, TSC, and AHN) showed uniform growth of 27-28% YoY.
Established a new 5,000 MTPA greenfield blending facility in Thailand through subsidiary Unistar Thai.
Completed the sale of the Andheri office as part of a strategy to monetize non-core assets.
👀 What to Watch
Investors should monitor the utilization levels of the new Thailand facility and the company's ability to pass through raw material costs to recover EBITDA margins toward the 12-13% range.
Rossari Biotech Q1 FY27: Revenue Grows 28% to ₹697 Cr; New 5,000 MTPA Thailand Facility Commissioned
Rossari Biotech reported a strong 28.2% YoY revenue growth to ₹697.2 Cr in Q1 FY27, driven by robust demand across its core HPPC, Textile, and Animal Health segments. While EBITDA grew 18.7% to ₹80.6 Cr, consolidated margins contracted by 90 bps to 11.6% due to higher operating costs and flat performance in the B2C segment. A key strategic milestone was the commissioning of a 5,000 MTPA greenfield blending facility in Thailand to serve Southeast Asia. The company also continued its non-core asset monetization by selling its Andheri office during the quarter.
Confidence: HIGH
What changedRossari has transitioned from domestic-heavy manufacturing to establishing an international production footprint in Thailand while delivering high double-digit top-line growth.
Why it mattersThe 28% revenue growth confirms strong market share gains in specialty chemicals, while the Thailand facility improves supply-chain efficiency for the Southeast Asian market, supporting the company's ₹3,500 Cr revenue potential target.
Q1 Revenue: ₹697.2 CrRevenue vs TTM: ~29%Thailand Capacity: 5,000 MTPAEBITDA Margin: 11.6%YoY Revenue Growth: 28.2%Finance Costs: ₹11.0 Cr
📅 Short termThe market is likely to react positively to the strong revenue beat and international expansion, though the 90 bps margin compression and high finance costs may temper the upside.
📈 Long termThe company is structurally positioned for growth with a diversified portfolio and new international capacity; achieving optimal utilization of its massive 387,100 MTPA total capacity is the key long-term value driver.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Margin contraction of 90 bps YoY
- 93% spike in finance costs
- Flat performance in Institutional and B2C segments
Key Highlights
Consolidated revenue reached ₹697.2 Cr, up 28.2% YoY, representing approximately 29% of TTM revenue.
Commissioned a new 5,000 MTPA greenfield facility in Thailand (Unistar Thai) for powders, granules, and liquids.
Core B2B business segments (excluding B2C/Institutional) delivered a superior EBITDA margin of 14%.
Segmental growth was broad-based: HPPC grew 28%, Textile Specialty Chemicals 28%, and Animal Health 27% YoY.
Finance costs increased significantly by 93% YoY to ₹11.0 Cr, impacting PAT growth which was limited to 4.5%.
👀 What to Watch
Monitor the capacity utilization of the new Thailand facility and the 367,100 MTPA domestic capacity to see if it drives ROCE back toward historical levels. Watch for margin recovery in the B2C and Institutional segments, which remained flat this quarter.
31.8% YoY Revenue Growth in Q1 FY27; Rossari Reports Standalone PAT of Rs 34.27 Cr
Rossari Biotech reported a strong year-on-year standalone performance for Q1 FY27, with revenue rising 31.8% to Rs 482.28 Cr compared to Rs 365.76 Cr in Q1 FY26. Standalone Profit After Tax (PAT) grew 30.6% YoY to Rs 34.27 Cr. However, performance weakened sequentially, with revenue down 6.5% and PAT down 37.4% from Q4 FY26 levels. The company also announced an internal restructuring to move its Saudi Arabian subsidiary under its Singapore entity to streamline global operations.
Confidence: HIGH
What changedRossari reported its Q1 FY27 financial results and initiated an internal corporate restructuring to consolidate overseas subsidiaries under a single Singapore-based holding platform.
Why it mattersThe strong YoY growth indicates robust demand in specialty chemicals, though the sequential decline suggests margin volatility or seasonal softness. The restructuring simplifies regulatory reporting for international operations.
Standalone Revenue (Q1 FY27): Rs 482.28 CrStandalone PAT (Q1 FY27): Rs 34.27 CrYoY Revenue Growth: 31.8%QoQ PAT Growth: -37.4%Q1 Revenue vs TTM Revenue: ~20.1%
📅 Short termThe stock may see positive sentiment from the strong YoY growth figures, although the sharp sequential drop in PAT might lead to some profit-taking or caution.
📈 Long termThe company remains focused on scaling its 367,100 MTPA capacity to reach a target revenue of Rs 3,500 Cr. Success depends on maintaining margins in the B2B specialty segment amidst raw material volatility.
⚠ Risk flags
- Significant sequential (QoQ) decline in profitability
- Limited pricing power due to intense competition from MNCs
- Raw material price volatility impacting margins
Key Highlights
Standalone Revenue from operations increased 31.8% YoY to Rs 482.28 Cr
Standalone PAT grew 30.6% YoY to Rs 34.27 Cr, though it fell 37.4% sequentially from Rs 54.73 Cr in Q4 FY26
Board approved the transfer of 100% shareholding of Rossari International Ltd (Saudi Arabia) to Rossari (Singapore) Pte. Ltd
Granted 4,000 stock options under ESOP 2019 at an exercise price of Rs 531 per share
Allotted 8,250 equity shares during the quarter following ESOP exercises, slightly increasing paid-up capital to Rs 11.08 Cr
👀 What to Watch
Investors should monitor the consolidated results to evaluate the performance of acquired subsidiaries like Unitop and Tristar, which are critical to the high-growth HPPC segment. Watch for management commentary on the sequential margin compression and the progress of the Rs 128 Cr ethoxylation capacity expansion.
Rossari Biotech Q1 Standalone PAT Up 30.6% YoY to ₹34.3 Cr; Consolidates Overseas Subsidiaries
Rossari Biotech reported a strong Q1 FY27 (ending June 2026) with standalone revenue growing 31.8% YoY to ₹482.28 cr. Standalone PAT increased 30.6% YoY to ₹34.27 cr, though it saw a sequential decline from the ₹54.7 cr reported in the previous quarter. The company also announced an internal restructuring to move its Saudi Arabian subsidiary under its Singapore entity to simplify overseas reporting. Additionally, the board approved a small ESOP grant of 4,000 options at ₹531 per share.
Confidence: HIGH
What changedRossari reported its Q1 FY27 financial results and initiated a corporate restructuring to consolidate all overseas subsidiaries under a single Singapore-based holding platform.
Why it mattersThe strong YoY revenue growth indicates robust demand in the specialty chemicals segment, while the restructuring simplifies international regulatory compliance and reporting lines.
Q1 Standalone Revenue: ₹482.28 crQ1 Standalone PAT: ₹34.27 crYoY Revenue Growth: 31.8%ESOP Exercise Price: ₹531Total Paid-up Capital: ₹11.08 cr
📅 Short termThe stock may react positively to the 30%+ YoY growth in both revenue and profit, although the sequential dip in PAT from Q4 may temper enthusiasm.
📈 Long termThe company is structurally focused on scaling its 367,100 MTPA capacity and expanding in MENA/Far East regions; the restructuring supports this international focus.
⚠ Risk flags
- Sequential decline in PAT compared to the March 2026 quarter
- Volatility in raw material prices and freight expenses
- Intense competition from MNCs in the specialty segment
Key Highlights
Standalone Revenue for Q1 FY27 rose to ₹482.28 cr from ₹365.76 cr in the same quarter last year.
Standalone Profit After Tax (PAT) stood at ₹34.27 cr, representing a 30.6% growth over Q1 FY26.
Internal restructuring approved to transfer 100% of Rossari International Limited Company (Saudi Arabia) to Rossari (Singapore) Pte. Ltd.
Board approved the grant of 4,000 ESOP options at an exercise price of ₹531, near the current market price.
Allotted 2,500 equity shares under the 2019 ESOP plan, marginally increasing paid-up capital to ₹11.08 cr.
👀 What to Watch
Investors should monitor the consolidated results to see if the strong standalone growth translates across the group, and track the progress of the Dahej unit ramp-up toward the ₹3,500 Cr revenue target.
Rs 482.3 Cr Q1 Standalone Revenue for Rossari Biotech, Up 31.8% YoY; Overseas Restructuring Set
Rossari Biotech reported a strong year-on-year performance for Q1 FY27, with standalone revenue rising 31.8% to Rs 482.3 Cr and PAT increasing 30.6% to Rs 34.3 Cr. However, performance weakened sequentially, with revenue and PAT declining 6.5% and 37.4% respectively compared to Q4 FY26. The board also approved an internal restructuring to consolidate all overseas subsidiaries under Rossari (Singapore) Pte. Ltd. to simplify regulatory reporting. Additionally, the company granted 4,000 ESOPs at an exercise price of Rs 531, aligning with the current market price.
Confidence: HIGH
What changedRossari released its Q1 FY27 standalone results and initiated an internal corporate restructuring to move its Saudi Arabian subsidiary under its Singapore holding company.
Why it mattersThe strong YoY growth indicates successful scaling of expanded capacities, though the sequential dip suggests potential margin pressure or seasonal demand fluctuations. The restructuring simplifies the international corporate structure for better regulatory compliance.
Standalone Revenue (Q1 FY27): Rs 482.3 CrYoY Revenue Growth: 31.8%QoQ PAT Growth: -37.4%Q1 Revenue vs TTM Revenue: ~20.1%ESOP Exercise Price: Rs 531
📅 Short termThe market is likely to view the robust YoY growth positively, although the sequential decline in profitability may lead to some caution in the immediate term.
📈 Long termThe company's focus on high-margin B2B segments and the consolidation of overseas units under a single platform are structural positives for long-term operational efficiency.
⚠ Risk flags
- Significant sequential (QoQ) decline in profitability
- Limited pricing power due to intense competition
- Volatility in raw material costs impacting margins
Key Highlights
Standalone Revenue for Q1 FY27 grew 31.8% YoY to Rs 482.3 Cr from Rs 365.8 Cr.
Standalone Profit After Tax (PAT) rose 30.6% YoY to Rs 34.3 Cr.
Sequential (QoQ) PAT saw a sharp decline of 37.4% from Rs 54.7 Cr in the preceding March quarter.
Approved 100% shareholding transfer of Rossari International Limited Company to Rossari (Singapore) Pte. Ltd.
Granted 4,000 stock options under ESOP 2019 at an exercise price of Rs 531 per share.
👀 What to Watch
Investors should monitor the consolidated financial statement to assess if the 31% standalone growth is reflected across the group's subsidiaries. Watch for management commentary on the sequential margin compression and the utilization levels of the recently commissioned 367,100 MTPA capacity.
Rossari Biotech Subsidiary Unistar Thai Sets Up 5000 MTPA Blending Facility in Thailand
Rossari Biotech's wholly-owned subsidiary, Unistar Thai Co. Limited, has established a new blending facility in Thailand with an installed capacity of 5,000 MTPA. Spanning approximately 1,860 square meters, the facility is designed to serve as a regional technical hub for the Southeast Asian market. This expansion allows for flexible manufacturing of powders, granules, and liquids, enabling the company to provide customized formulations locally. The move follows the 100% acquisition of Unistar in December 2024 and is expected to enhance supply chain resilience and operational efficiency.
Key Highlights
Installed capacity of 5,000 MTPA at the new Thailand blending facility
Facility covers a land area of approximately 1,860 square meters
Strategic regional technical hub for the Southeast Asian market to provide customized formulations
Flexible manufacturing capabilities across powders, granules, and liquids with dedicated storage for surfactants
Follow-up to the 100% equity acquisition of Unistar Thai Co. Limited completed in December 2024
👀 What to Watch
Investors should monitor the ramp-up of this facility as it marks a significant step in Rossari's international expansion and localized manufacturing strategy. Positive impact on margins and market share in Southeast Asia is expected over the medium term.
Rossari Biotech Schedules 17th AGM for July 20, 2026; Sets July 10 as Dividend Record Date
Rossari Biotech Limited has scheduled its 17th Annual General Meeting (AGM) for July 20, 2026, to be conducted via video conferencing. The company has established July 10, 2026, as the record date to determine shareholder eligibility for the dividend for the financial year 2025-26. If approved at the AGM, the dividend will be disbursed within 10 working days from the meeting date. Furthermore, July 13, 2026, has been fixed as the cut-off date for participating in the electronic voting process.
Key Highlights
17th Annual General Meeting (AGM) to be held on Monday, July 20, 2026, at 11:00 A.M. IST.
Record date for determining dividend entitlement for FY 2025-26 is Friday, July 10, 2026.
Dividend payment will be completed within 10 working days from the conclusion of the AGM, subject to shareholder approval.
Cut-off date for remote e-voting and e-voting during the AGM is fixed as Monday, July 13, 2026.
The dividend pertains to equity shares with a face value of Rs. 2/- each.
👀 What to Watch
Investors interested in receiving the dividend should ensure they hold the company's shares by the record date of July 10, 2026. Shareholders are also encouraged to participate in the e-voting process starting from the cut-off date of July 13.
Rossari Biotech Sets July 10, 2026 as Record Date for Final Dividend of FY 2025-26
Rossari Biotech Limited has announced its 17th Annual General Meeting (AGM) for July 20, 2026. The company has fixed July 10, 2026, as the record date to determine eligibility for the final dividend for the financial year 2025-26. Shareholders as of this date will be entitled to the payout, which will be processed within 10 working days of the AGM. Additionally, July 13, 2026, has been designated as the cut-off date for e-voting eligibility.
Key Highlights
17th Annual General Meeting scheduled for Monday, July 20, 2026, at 11:00 A.M. IST.
Record date for final dividend entitlement is fixed as Friday, July 10, 2026.
Cut-off date for remote e-voting and AGM voting is Monday, July 13, 2026.
Dividend payment will be completed within 10 working days from the conclusion of the AGM.
The dividend pertains to equity shares with a face value of Rs. 2/- each for FY 2025-26.
👀 What to Watch
Investors interested in receiving the final dividend should ensure they hold the company's shares in their demat account before the record date of July 10, 2026.
Rossari Biotech Faces Legal Challenge to Unitop Chemicals Arbitration Award
Rossari Biotech has been served a petition by the former shareholders of its material subsidiary, Unitop Chemicals Private Limited, challenging a previous arbitration award. The Sellers filed the petition under Section 34 of the Arbitration and Conciliation Act, 1996, on June 04, 2026, contesting the final award issued on January 21, 2026. This dispute originates from the Share Purchase Agreement (SPA) signed on June 02, 2021, for the acquisition of Unitop. The ongoing litigation adds a layer of legal uncertainty regarding the final settlement terms of this material acquisition.
Key Highlights
Sellers of Unitop Chemicals challenged the Arbitral Tribunal's final award dated January 21, 2026.
The petition was served to Rossari Biotech on June 04, 2026, under Section 34 of the Arbitration and Conciliation Act.
The dispute relates to the Share Purchase Agreement (SPA) executed on June 02, 2021.
Unitop Chemicals is classified as a material unlisted subsidiary of Rossari Biotech Limited.
The challenge indicates that the legal resolution regarding the acquisition terms is not yet finalized.
👀 What to Watch
Investors should monitor the progress of this litigation as it may affect the final cash outflow or valuation adjustments related to the Unitop acquisition. No immediate portfolio changes are recommended, but the legal contingency should be factored into the company's risk profile.
Rossari Biotech to Grant 8.30 Lakh ESOPs at Rs 537; Re-appoints Independent Director
Rossari Biotech's board has approved the grant of 830,050 stock options under its 2019 ESOP plan at an exercise price of Rs 537 per share. The options follow a staggered vesting schedule over four years (20%, 20%, 20%, and 40%) and are exercisable within five years of vesting. Additionally, the board has recommended the re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a second three-year term starting October 21, 2026. These actions reflect the company's focus on talent retention and board continuity.
Key Highlights
Grant of 830,050 stock options to eligible employees under the ESOP 2019 scheme.
Exercise price for the options is fixed at Rs 537 per share.
Vesting schedule is spread over 4 years: 20% annually for 3 years and 40% in the 4th year.
Re-appointment of Ms. Esha Padmanabhan Achan as Independent Director for a 3-year term until October 2029.
Ms. Achan brings 33 years of senior management experience from companies like Glenmark and Bajaj.
👀 What to Watch
Investors should monitor the potential equity dilution resulting from the 8.30 lakh shares and view the board re-appointment as a sign of governance stability.
Rossari Biotech Reports Record Q4 Revenue of ₹685 Cr; FY26 Revenue Up 15% to ₹2,396 Cr
Rossari Biotech achieved its highest-ever quarterly revenue and EBITDA in Q4 FY26, with revenue growing 18% YoY to ₹684.9 crore. For the full year FY26, the company reported a 15% revenue growth to ₹2,396.4 crore, supported by strong volume growth across HPPC, Textiles, and Animal Health segments. While overall EBITDA margins contracted slightly to 11.9% due to raw material volatility, the core B2B business maintained a robust 14% margin. Management has guided for at least 15% growth in FY27 with margins expected to stabilize between 12-13%.
Key Highlights
Q4 FY26 marked record quarterly performance with revenue of ₹684.9 crore and EBITDA of ₹77.3 crore.
Full-year FY26 revenue grew 15% to ₹2,396.4 crore, primarily driven by volume growth and an 11% increase in exports.
Ethoxylation capacity at Dahej (Unitop) was expanded to 66,000 MTPA to enhance supply reliability.
Core B2B operations delivered a healthy 14% EBITDA margin, offsetting losses in the subdued B2C and institutional segments.
Company is re-evaluating and re-phasing its ₹192 crore CAPEX plan to align with evolving market conditions.
👀 What to Watch
Investors should focus on the company's ability to pass on raw material price hikes and the scaling of its new R&D and ethoxylation capacities. The shift toward higher-margin segments like pharma and biosurfactants provides a positive long-term outlook for margin expansion.
Rossari Biotech Reports Record Q4 FY26 Revenue of ₹685 Cr, PAT Up 34% YoY
Rossari Biotech achieved its highest-ever quarterly revenue and EBITDA in Q4 FY26, driven by double-digit growth across all business segments including HPPC, TSC, and AHN. For the full year FY26, revenue grew 15.2% to ₹2,396.4 crore, though EBITDA margins slightly compressed to 11.9% from 12.7% due to raw material cost volatility. The company successfully commissioned an additional 15,000 MTPA ethoxylation capacity at Dahej, bringing the total to 66,000 MTPA. A dividend of ₹0.50 per share has been recommended for the fiscal year.
Key Highlights
Q4 FY26 Revenue grew 18.2% YoY to ₹684.9 crore, the highest quarterly performance to date.
Quarterly Net Profit (PAT) surged 33.7% YoY to ₹46.0 crore in Q4 FY26.
Full-year FY26 Revenue reached ₹2,396.4 crore with a consolidated PAT of ₹149.2 crore.
Commissioned 15,000 MTPA ethoxylation capacity at Dahej facility on March 31, 2026.
Net Debt to Equity remains healthy at 0.21x despite ongoing capital expenditure.
👀 What to Watch
Investors should focus on the company's ability to pass on raw material costs to recover margins and the scaling of the newly added ethoxylation capacity. The narrowing losses in the B2C segment and strong core B2B growth suggest a positive outlook for the specialty chemicals platform.
Rossari Biotech Q4 FY26 PAT Jumps 34% YoY to ₹46 Cr; Revenue Up 18% to ₹684.9 Cr
Rossari Biotech reported its highest-ever quarterly revenue of ₹684.9 crore for Q4 FY26, marking an 18% YoY growth driven by strong performance across all business segments. While EBITDA grew 11% to ₹77.3 crore, EBITDA margins contracted slightly to 11.3% from 12.0% due to raw material cost inflation and pricing lags. Net profit (PAT) saw a significant surge of 34% YoY to ₹46.0 crore. The company also successfully commissioned additional ethoxylation capacity at Dahej, bringing the total to 66,000 MTPA, and recommended a dividend of ₹0.50 per share.
Key Highlights
Q4 FY26 Revenue from operations grew 18% YoY to ₹684.9 crore, the highest quarterly revenue ever.
Consolidated PAT for Q4 FY26 increased by 34% YoY to ₹46.0 crore from ₹34.4 crore.
EBITDA margins compressed to 11.3% in Q4 FY26 compared to 12.0% in the previous year's quarter.
Unitop commissioned 15,000 MTPA additional ethoxylation capacity at Dahej, reaching a total of 66,000 MTPA.
The Board recommended a dividend of ₹0.50 per share for the financial year 2025-26.
👀 What to Watch
Investors should monitor the company's ability to pass on raw material costs to recover margins in the coming quarters. The strong top-line growth and capacity expansion indicate a robust demand outlook, supporting a positive long-term view.
Rossari Biotech Declares Rs 0.50 Dividend and Reschedules Capacity Expansion Project
Rossari Biotech has approved its audited FY26 financial results and recommended a final dividend of Rs. 0.50 per share (25% of face value). The company is rescheduling its previously announced capacity expansion project, which will now be implemented in a phased manner over the next two years to align with market conditions. A new R&D facility has been established in Navi Mumbai to consolidate innovation efforts. Additionally, the board appointed industry veteran Mr. Udeypaul Singh Gill as an Independent Director for a three-year term.
Key Highlights
Recommended a final dividend of 25% (Rs. 0.50 per share) for the financial year ended March 31, 2026.
Rescheduled the major capacity expansion project to a phased implementation over the next 24 months.
Established a new Research and Development facility in Navi Mumbai, relocating operations from IIT Bombay.
Appointed Mr. Udeypaul Singh Gill, a leader with 40+ years of experience, as an Independent Director.
Allotted 8,250 equity shares under the ESOP 2019 plan at an exercise price of Rs. 425 per share.
👀 What to Watch
Investors should monitor the reasons behind the expansion delay and how the phased rollout affects revenue growth targets. The focus on R&D and the addition of a seasoned board member are positive for long-term strategic positioning.
Rossari Biotech Declares Rs 0.50 Dividend, Appoints New Director, and Reschedules Expansion
Rossari Biotech's board has recommended a final dividend of 25% (Rs. 0.50 per share) for the financial year ended March 31, 2026. The company is rescheduling its previously announced capacity expansion project to a phased implementation over the next two years due to evolving market conditions. Additionally, the company has established a new R&D facility in Navi Mumbai to enhance innovation capabilities and appointed Mr. Udeypaul Singh Gill, a veteran with 40 years of experience, as an Independent Director. The board also approved the allotment of 8,250 equity shares under its ESOP scheme at an exercise price of Rs. 425.
Key Highlights
Recommended a final dividend of Rs. 0.50 per share (25% of face value Rs. 2) for FY 2025-26.
Rescheduled capacity expansion project to be implemented in a phased manner over the next 24 months.
Appointed Mr. Udeypaul Singh Gill as an Independent Director for a 3-year term starting April 28, 2026.
Established a new R&D facility in Navi Mumbai, relocating operations from the existing IIT Bombay facility.
Allotted 8,250 equity shares under ESOP 2019, increasing paid-up capital to Rs. 11.08 crore.
👀 What to Watch
Investors should monitor the management's commentary regarding the rescheduling of the expansion project to understand if demand is softening. The focus remains on the successful integration of the new R&D facility to drive long-term product innovation.
Rossari Biotech: Re. 0.50 Dividend, ESOP Allotment, and Capacity Expansion Update
Rossari Biotech's board has approved a final dividend of Re. 0.50 per share (25%) for the financial year ended March 31, 2026. The company also allotted 8,250 equity shares under its ESOP 2019 plan at an exercise price of Rs. 425 per share. Crucially, the company is rescheduling its previously announced capacity expansion project to a phased implementation over the next two years. To bolster innovation, a new R&D facility has been established in Navi Mumbai, and Mr. Udeypaul Singh Gill has been appointed as an Independent Director.
Key Highlights
Recommended a final dividend of Re. 0.50 per equity share (25% of face value Rs. 2) for FY 2025-26.
Allotted 8,250 equity shares under ESOP 2019, increasing paid-up capital to Rs. 11.08 crore.
Rescheduled the capacity expansion project to a phased rollout over the next 24 months due to market conditions.
Established a new R&D facility in Navi Mumbai and relocated existing IIT Bombay operations there.
Appointed Mr. Udeypaul Singh Gill as an Independent Director for a three-year term starting April 28, 2026.
👀 What to Watch
Investors should monitor the impact of the delayed capacity expansion on long-term growth targets while noting the company's continued focus on R&D. The dividend is modest, so the focus remains on the upcoming full audited financial performance details.
Rossari Biotech Recommends Rs 0.50 Dividend and Reschedules Capacity Expansion Project
Rossari Biotech has recommended a final dividend of Rs. 0.50 per share (25% of face value) for the financial year ended March 31, 2026. The company is re-evaluating its previously announced capacity expansion project, which will now be implemented in a phased manner over the next two years instead of the original timeline. To bolster innovation, the company has established a new R&D facility in Navi Mumbai, shifting operations from its existing IIT Bombay site. Additionally, the board approved the appointment of industry veteran Mr. Udeypaul Singh Gill as an Independent Director.
Key Highlights
Recommended final dividend of Rs. 0.50 per share (25%) on equity shares of face value Rs. 2 each.
Rescheduled capacity expansion project to be implemented in a phased manner over the next 24 months.
Established a new Research and Development facility at Navi Mumbai to enhance innovation and product development.
Allotted 8,250 equity shares under the Rossari Employee Stock Option Plan - 2019 at an exercise price of Rs. 425.
Appointed Mr. Udeypaul Singh Gill as an Independent Director for a three-year term starting April 28, 2026.
👀 What to Watch
Investors should monitor the impact of the rescheduled capacity expansion on long-term growth targets while noting the company's increased focus on R&D. The dividend yield remains modest, so the primary focus should be on the execution of the phased investment plan.
Rossari Biotech Declares Rs 0.50 Dividend and Reschedules Capacity Expansion Project
Rossari Biotech has approved its audited financial results for FY26 and recommended a final dividend of Rs. 0.50 per share (25% of face value). The company is rescheduling its major capacity expansion project to a phased implementation over the next two years to align with market conditions. In a move to boost innovation, a new R&D facility has been established in Navi Mumbai, replacing the existing IIT Bombay unit. Additionally, the board appointed Mr. Udeypaul Singh Gill as an Independent Director and allotted 8,250 shares under its ESOP scheme.
Key Highlights
Recommended a final dividend of Rs. 0.50 per equity share (25%) for the financial year 2025-26.
Rescheduled the implementation of its capacity expansion project to a phased manner over the next two years.
Established a new Research and Development facility in Navi Mumbai, relocating from the IIT Bombay site.
Appointed Mr. Udeypaul Singh Gill as an Independent Director for a three-year term starting April 28, 2026.
Allotted 8,250 equity shares under the ESOP 2019 plan at an exercise price of Rs. 425 per share.
👀 What to Watch
Investors should monitor the reasons for the expansion delay and the impact of the new R&D facility on product innovation. The dividend yield is relatively low, so focus should remain on the company's ability to execute its phased growth strategy.
